Literature DB >> 6683996

The regulation of tissue plasminogen activator activity by human fibroblasts.

E G Hoal, E L Wilson, E B Dowdle.   

Abstract

We have found that live and ethanol-fixed fibroblasts, when covered with conditioned medium containing tissue plasminogen activator, associate with the enzyme and remove it from the medium. Binding of tissue plasminogen activator to fixed cells showed equilibrium kinetics with maximal uptake corresponding to 2.4 units of enzyme per 10(6) fixed cells. Enzyme bound to fixed cells could activate plasminogen and produce plaques of caseinolysis in casein-plasminogen-agar overlays. Electrophoretic analysis showed it covalently attached to a fibroblast component with a molecular weight of 40,000-50,000. Sequestration of tissue plasminogen activator by live fibroblasts showed nonsaturable first order kinetics with a rate constant of 0.465/hr. We conclude that active enzyme is bound to a surface receptor, then internalized and degraded. Fibroblasts did not release the binding molecule into the medium; binding of tissue plasminogen activator from the medium was unaffected by heparin or thrombin. This phenomenon differs from that described by Baker et al. and ascribed to "proteasenexin."

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683996     DOI: 10.1016/0092-8674(83)90158-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  13 in total

1.  Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.

Authors:  T Ny; M Sawdey; D Lawrence; J L Millan; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

2.  Proteolytic enzymes and arachidonic acid metabolites produced by MRC-5 cells on various microcarrier substrates.

Authors:  J Varani; J D Hasday; R G Sitrin; P G Brubaker; W A Hillegas
Journal:  In Vitro Cell Dev Biol       Date:  1986-10

3.  Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.

Authors:  J Bizik; A Lizonová; R W Stephens; M Grófová; A Vaheri
Journal:  Cell Regul       Date:  1990-11

4.  Induction of urokinase-type plasminogen activator by UV light in human fetal fibroblasts is mediated through a UV-induced secreted protein.

Authors:  N Rotem; J H Axelrod; R Miskin
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

5.  Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator.

Authors:  R L Silverstein; L L Leung; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

6.  Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin.

Authors:  L Ossowski; D Belin
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

7.  Continuous production of tissue plasminogen activator (t-PA) by human embryonic lung diploid fibroblast, IMR-90 cells, using a ceramic bed reactor.

Authors:  S Mitsuda; Y Matsuda; N Kobayashi; A Suzuki; Y Itagaki; E Kumazawa; K Higashio; G Kawanishi
Journal:  Cytotechnology       Date:  1991-05       Impact factor: 2.058

8.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

9.  Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.

Authors:  R Picone; E L Kajtaniak; L S Nielsen; N Behrendt; M R Mastronicola; M V Cubellis; M P Stoppelli; S Pedersen; K Danø; F Blasi
Journal:  J Cell Biol       Date:  1989-02       Impact factor: 10.539

10.  In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases.

Authors:  P Mignatti; R Tsuboi; E Robbins; D B Rifkin
Journal:  J Cell Biol       Date:  1989-02       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.